Browse list of available series in The Biomedical & Life Sciences Collection
Recommend The Biomedical & Life Sciences Collection to your librarian
Request to be kept updated on The Biomedical & Life Sciences Collection
Apply for a free trial of The Biomedical & Life Sciences Collection
View all talks & series with full access

Guest (sample access)

Optional Login with Username


        
> Home  /  Biomedical & Life Sciences  /  Series  /  Protein Epidemiology  /  Talk Details
SHARE:   Email via Outlook   Email via Web   Facebook   Twitter   |   more
Close SHARE
Please select one of the methods below to share the following page with your collegues:
Metachromatic Leukodystrophy
Blogger Google Reader
Delicious Linked In
Digg MySpace
Favorites PDF Online
Gmail

Hello. As a guest, you do not have full access to this talk. Click the PLAY button below to watch the sample extract. Alternatively, you may login or review methods of obtaining more access.

Printable Slide
Handouts PDF
Metachromatic Leukodystrophy - play sample talk extract

    SPEAKER(S)

Prof. Volkmar Gieselmann - Institut fur Physiologische Chemie, University of Bonn, Germany

Volkmar Gieselmann is Professor of Biochemistry in the Medical Faculty of the University of Bonn. He has a long-standing interest in lysosomal storage disorders, in particular in metachromatic leukodystrophy. He has cloned the defective gene in this disease, characterized the effects of a number of mutations on the biochemical level and generated an animal model. He is currently the chairman of the Institute of Physiological Chemistry.

Talk Online Publication: Oct 2007

TOPICS COVERED IN METACHROMATIC LEUKODYSTROPHY

Metabolic defect in metachromatic leukodystrophy - Genetics - Genotype/phenotype correlations - Biochemical consequences of selected mutations - Diganostic problems due to arylsulfatase A pseudodeficiency - Gene therapy and enzyme replacement trials in an animal model

How to cite this talk:
Gieselmann, V. (2007), "Metachromatic Leukodystrophy", in Dunn, B. (ed.), Protein Epidemiology: Understanding Human Diseases at the Level of Protein Structure and Function, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/bio)

Direct talk access link:
http://hstalks.com/lib.php?t=HST10.1174_1_2&c=252

    DETAILED SLIDE INDEX

1. Introduction
2. Outline
3. MLD is a lysosomal storage disorder
4. Degradation of sulfatide by ASA
5. Myelin is a membrane of oligodendrocytes
6. Demyelination is a pathology of MLD
7. Patient suffering from MLD
8. Handwriting of a MLD patient
9. MLD is clinically heterogeneous
10. Genetics of MLD
11. Structure of the human ASA gene
12. 3 mRNA generated from ASA gene
13. Mutations in the human ASA gene
14. Only three mutations are frequent
15. Genotype-phenotype correlation in MLD
16. ASA activity in fibroblasts
17. Biochemical consequences of mutations
18. Molecular explanations for complete activity loss
19. Different types of mutations in ASA gene
20. Structure of human ASA
21. Many defective ASA are severely misfolded
22. Molecular basis for residual ASA activity
23. ASA dimers form octamers in the lysosome
24. ASA forms octamers
25. Pro 426 is involved in octamerization
26. Consequences of Pro 426 for leucine substitution
27. ASA pseudodeficiency
28. Deficiency of ASA is not a proof for MLD
29. Size of pseudodeficiency ASA
30. Glycosylation sites in ASA pseudodeficiency
31. Amount of pseudodeficiency ASA
32. ASA mRNA species in pseudodeficiency
33. Possible changes in mRNA species
34. Structure of the ASA pseudodeficiency allele
35. Diagnostic example
36. Therapeutic trials in a mouse model
37. Sulfatide storage in the brain of ASA deficient mice
38. Sulfatide storage in glia and neurons
39. Ultrastructure of storage material (1)
40. Ultrastructure of storage material (2)
41. ASA deficient mice do not demyelinate
42. Acoustic ganglion degeneration
43. Progressive neurologic symptoms
44. Properties of ASA deficient mice
45. Therapeutic trials in ASA knock out mice
46. AAV5 ASA injections in ASA knock out mice
47. Reduction of sulfatide storage after injections
48. Functional improvements after injections
49. Enzyme replacement studies
50. Sulfatide reduction in kidney after ASA injection
51. Sulfatide reduction in sciatic nerve
52. CNS pathology after 4 weekly doses of ASA (1)
53. CNS pathology after 4 weekly doses of ASA (2)
54. Improvement of neurologic symptoms
55. Summary
56. END